{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T20:45:15Z","timestamp":1771620315638,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["FIS\/ISC III\/FEDER PI22\/00171"],"award-info":[{"award-number":["FIS\/ISC III\/FEDER PI22\/00171"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["MICIU\/AEI \/10.13039\/501100011033"],"award-info":[{"award-number":["MICIU\/AEI \/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010148","name":"Spanish Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010148","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018967","name":"Universitat Pompeu Fabra","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018967","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["2015\/3211\/I"],"award-info":[{"award-number":["2015\/3211\/I"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.labinv.2025.104171","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:52:08Z","timestamp":1744149128000},"page":"104171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer"],"prefix":"10.1016","volume":"105","author":[{"given":"Laura","family":"Segal\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6809-132X","authenticated-orcid":false,"given":"J\u00falia","family":"Perera-Bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1378-736X","authenticated-orcid":false,"given":"Gardenia","family":"Vargas-Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Juanpere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-5085","authenticated-orcid":false,"given":"Llu\u00eds","family":"Colomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Llu\u00eds","family":"Cecchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Lloreta-Trull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Y\u00e9lamos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Llu\u00eds","family":"Fumad\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Hern\u00e1ndez-Llodr\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.labinv.2025.104171_bib1","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1186\/s12889-023-17440-7","article-title":"Significantly reduced incidence and improved survival from prostate cancer over 25 years","volume":"23","author":"Serd\u00e0-Ferrer","year":"2023","journal-title":"BMC Public Health"},{"key":"10.1016\/j.labinv.2025.104171_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.labinv.2025.104171_bib3","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.eururo.2020.01.033","article-title":"Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review","volume":"77","author":"Moris","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.labinv.2025.104171_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.labinv.2025.104171_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.labinv.2025.104171_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241258443","article-title":"Androgen receptor, PARP signaling, and tumor microenvironment: the \u2018perfect triad\u2019 in prostate cancer?","volume":"16","author":"Garofoli","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.labinv.2025.104171_bib7","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.3390\/cells9122653","article-title":"Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications","volume":"9","author":"Aurilio","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.labinv.2025.104171_bib8","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3389\/fonc.2019.01263","article-title":"A New era of prostate cancer precision medicine","volume":"9","author":"Malik","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.labinv.2025.104171_bib9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/cancers14071803","article-title":"Androgen deprivation therapy in high-risk localized and locally advanced prostate cancer","volume":"14","author":"Iwamoto","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.labinv.2025.104171_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231221337","article-title":"Development of PARP inhibitors in advanced prostate cancer","volume":"16","author":"Bourlon","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.labinv.2025.104171_bib11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.labinv.2025.104171_bib12","first-page":"189","article-title":"Molecular mechanisms of enzalutamide resistance in prostate cancer","volume":"2","author":"Blatt","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.labinv.2025.104171_bib13","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3390\/cancers13071534","article-title":"Androgen receptor-dependent mechanisms mediating drug resistance in prostate cancer","volume":"13","author":"Ehsani","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.labinv.2025.104171_bib14","doi-asserted-by":"crossref","first-page":"728.e13","DOI":"10.1016\/j.urolonc.2021.01.030","article-title":"Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer","volume":"39","author":"Csizmarik","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.labinv.2025.104171_bib15","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.labinv.2025.104171_bib16","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and Resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.labinv.2025.104171_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clgc.2016.08.018","article-title":"Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH","volume":"15","author":"Moreira","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.labinv.2025.104171_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/bju.15084","article-title":"The genetic landscapes of urological cancers and their clinical implications in the era of high-throughput genome analysis","volume":"126","author":"Light","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.labinv.2025.104171_bib19","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3390\/genes11121396","article-title":"The genetic complexity of prostate cancer","volume":"11","author":"Comp\u00e9rat","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.labinv.2025.104171_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147878","article-title":"Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.labinv.2025.104171_bib21","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.labinv.2025.104171_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11912-018-0707-9","article-title":"Molecular subtypes of prostate cancer","volume":"20","author":"Arora","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.labinv.2025.104171_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MOU.0000000000000285","article-title":"Molecular subtyping of prostate cancer","volume":"26","author":"Kaffenberger","year":"2016","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.labinv.2025.104171_bib24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.labinv.2025.104171_bib25","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ng.371","article-title":"Cooperativity of TMPRSS2::ERG with PI3-kinase pathway activation in prostate oncogenesis","volume":"41","author":"King","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.labinv.2025.104171_bib26","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/modpathol.2009.69","article-title":"Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression","volume":"22","author":"Han","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.labinv.2025.104171_bib27","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/modpathol.2008.96","article-title":"Absence of TMPRSS2::ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome","volume":"21","author":"Yoshimoto","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.labinv.2025.104171_bib28","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/pros.23176","article-title":"Concurrent TMPRSS2::ERG and SLC45A3::ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset","volume":"76","author":"Hern\u00e1ndez","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.labinv.2025.104171_bib29","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/pros.23004","article-title":"Association of ERG and TMPRSS2::ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels","volume":"75","author":"Font-Tello","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.labinv.2025.104171_bib30","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41391-020-00314-z","article-title":"Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2::ERG fusions","volume":"24","author":"Chalmers","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.labinv.2025.104171_bib31","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.labinv.2025.104171_bib32","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"Mateo","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.labinv.2025.104171_bib33","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3390\/cancers15092435","article-title":"Frequency of germline and somatic BRCA1 and BRCA2 mutations in prostate cancer: an updated systematic review and meta-analysis","volume":"15","author":"Valsecchi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.labinv.2025.104171_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13671","article-title":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","volume":"8","author":"Taylor","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.labinv.2025.104171_bib35","doi-asserted-by":"crossref","first-page":"8154","DOI":"10.1002\/cam4.5617","article-title":"Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer","volume":"12","author":"Nukaya","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.labinv.2025.104171_bib36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.eururo.2022.08.010","article-title":"Analysis of BRCA2 copy number loss and genomic instability in circulating tumor cells from patients with metastatic castration-resistant prostate cancer","volume":"83","author":"Barnett","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.labinv.2025.104171_bib37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer","volume":"541","author":"Fraser","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.labinv.2025.104171_bib38","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"17","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.labinv.2025.104171_bib39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration- resistant prostate cancer catherine","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.labinv.2025.104171_bib40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-019-0153-2","article-title":"Role of the DNA damage response in prostate cancer formation, progression and treatment","volume":"23","author":"Zhang","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.labinv.2025.104171_bib41","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.labinv.2025.104171_bib42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/cancers11030352","article-title":"BRCA2 and other DDR genes in prostate cancer","volume":"11","author":"Nombela","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.labinv.2025.104171_bib43","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1007\/s12325-024-02844-7","article-title":"Homologous recombination repair gene mutations in prostate cancer: prevalence and clinical value","volume":"41","author":"Fan","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.labinv.2025.104171_bib44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.labinv.2025.104171_bib45","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.labinv.2025.104171_bib46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","article-title":"DNA repair in prostate cancer: biology and clinical implications","volume":"71","author":"Mateo","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.labinv.2025.104171_bib47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.eururo.2018.01.010","article-title":"Clinical outcome of prostate cancer patients with germline DNA Repair mutations: retrospective analysis from an international study","volume":"73","author":"Mateo","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.labinv.2025.104171_bib48","doi-asserted-by":"crossref","first-page":"805","DOI":"10.20892\/j.issn.2095-3941.2020.0177","article-title":"Evolving insights: how DNA repair pathways impact cancer evolution","volume":"17","author":"Zhou","year":"2020","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.labinv.2025.104171_bib49","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.labinv.2025.104171_bib50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41391-018-0086-1","article-title":"Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage","volume":"22","author":"Marshall","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.labinv.2025.104171_bib51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/onco.13585","article-title":"FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA-mutated metastatic castrate-resistant prostate cancer","volume":"26","author":"Anscher","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.labinv.2025.104171_bib52","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.23.01868","article-title":"FDA approval summary: olaparib in combination with abiraterone for treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.labinv.2025.104171_bib53","doi-asserted-by":"crossref","first-page":"11488","DOI":"10.1021\/acs.jmedchem.4c00113","article-title":"New horizons of synthetic lethality in cancer: current development and future perspectives","volume":"67","author":"Previtali","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.labinv.2025.104171_bib54","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.labinv.2025.104171_bib55","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/blood.2021012805","article-title":"Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice","volume":"139","author":"Galindo-Campos","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.labinv.2025.104171_bib56","first-page":"328","article-title":"PARP-1 and PARP-2: new players in tumour development","volume":"1","author":"Yelamos","year":"2011","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.labinv.2025.104171_bib57","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2024.14","article-title":"Specific and shared biological functions of PARP2 - is PARP2 really a lil\u2019 brother of PARP1?","volume":"26","author":"Sz\u00e1nt\u00f3","year":"2024","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.labinv.2025.104171_bib58","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.labinv.2025.104171_bib59","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-23-2094","article-title":"Preclinical characterization of AZD9574, a blood-brain barrier penetrant inhibitor of PARP1","volume":"30","author":"Staniszewska","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.labinv.2025.104171_bib60","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/754190","article-title":"Deficiency in poly(ADP-ribose) polymerase-1 (PARP-1) accelerates aging and spontaneous carcinogenesis in mice","volume":"2008","author":"Piskunova","year":"2008","journal-title":"Curr Gerontol Geriatr Res"},{"key":"10.1016\/j.labinv.2025.104171_bib61","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.labinv.2025.104171_bib62","doi-asserted-by":"crossref","first-page":"14573","DOI":"10.1073\/pnas.1908547116","article-title":"Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function","volume":"116","author":"Gui","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.labinv.2025.104171_bib63","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.3390\/ijms24043083","article-title":"Preclinical efficacy of a PARP-1 targeted auger-emitting radionuclide in prostate cancer","volume":"24","author":"Sreekumar","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.labinv.2025.104171_bib64","article-title":"Pan-cancer analysis of PARP1 alterations as biomarkers in the prediction of immunotherapeutic effects and the association of its expression levels and immunotherapy signatures","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.labinv.2025.104171_bib65","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12894-024-01563-z","article-title":"Analysis of risk factors for persistent PSA after radical prostatectomy: results from a high-volume center in Southeast China","volume":"24","author":"Hao","year":"2024","journal-title":"BMC Urol"},{"key":"10.1016\/j.labinv.2025.104171_bib66","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, Part II: principles of active surveillance, principles of surgery, and follow-up","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.labinv.2025.104171_bib67","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ijc.34947","article-title":"PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma","volume":"155","author":"Fr\u00f6hlich","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.labinv.2025.104171_bib68","doi-asserted-by":"crossref","first-page":"46348","DOI":"10.18632\/oncotarget.18013","article-title":"PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma","volume":"8","author":"Murny\u00e1k","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.labinv.2025.104171_bib69","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/annonc\/mdr361","article-title":"Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer","volume":"23","author":"Rojo","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.labinv.2025.104171_bib70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/cells9010041","article-title":"Multifaceted role of parp-1 in dna repair and inflammation: pathological and therapeutic implications in cancer and non-cancer diseases","volume":"9","author":"Pazzaglia","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.labinv.2025.104171_bib71","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.3892\/ol.2016.5169","article-title":"High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer","volume":"12","author":"Liu","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.labinv.2025.104171_bib72","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","article-title":"Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1","volume":"2","author":"Byers","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.labinv.2025.104171_bib73","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.humpath.2013.01.015","article-title":"Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival","volume":"44","author":"Gan","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.labinv.2025.104171_bib74","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s12885-020-06903-4","article-title":"Different regulation of PARP1, PARP2, PARP3 and TRPM2 genes expression in acute myeloid leukemia cells","volume":"20","author":"Gil-Kulik","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.labinv.2025.104171_bib75","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3121\/cmr.2021.1607","article-title":"Immunohistochemical Evaluation of PARP and caspase-3 as prognostic markers in prostate carcinomas","volume":"19","author":"Acar","year":"2021","journal-title":"Clin Med Res"},{"key":"10.1016\/j.labinv.2025.104171_bib76","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s11255-014-0642-0","article-title":"Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients","volume":"46","author":"Wu","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.labinv.2025.104171_bib77","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.3390\/cancers12102907","article-title":"PARP1 deficiency reduces tumour growth by decreasing E2F1 hyperactivation: a novel mechanism beyond PARP enzymatic inhibition in the treatment of cancer","volume":"12","author":"Iglesias","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.labinv.2025.104171_bib78","doi-asserted-by":"crossref","first-page":"E4061","DOI":"10.1073\/pnas.1712345115","article-title":"PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression","volume":"115","author":"D\u00f6rsam","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.labinv.2025.104171_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.tem.2024.12.003","article-title":"Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer","author":"Brea","year":"2025","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.labinv.2025.104171_bib80","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.labinv.2025.104171_bib81","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.labinv.2025.104171_bib82","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","article-title":"Abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (BRCAAway)","volume":"30","author":"Hussain","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.labinv.2025.104171_bib83","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2147\/CMAR.S411023","article-title":"Integrating PARP inhibitors in mCRPC therapy: current strategies and emerging trends","volume":"16","author":"Thapa","year":"2024","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.labinv.2025.104171_bib84","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683725000819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683725000819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:59:16Z","timestamp":1762210756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683725000819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0023683725000819"],"URL":"https:\/\/doi.org\/10.1016\/j.labinv.2025.104171","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.labinv.2025.104171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104171"}}